Advertisement

Topics

Circassia Announces Duaklir Successfully Met Primary Endpoints In AMPLIFY Phase III Study In Chronic Obstructive Pulmonary Disease

20:00 EDT 6 Sep 2017 | BioSpace

OXFORD, UNITED KINGDOM--(Marketwired - September 07, 2017) - Circassia Pharmaceuticals Plc (LSE: CIR)(LSE: CIR)Circassia Announces Duaklir® Successfully Met Primary Endpoints in AMPLIFY Phase III Study in Chronic Obstructive Pulmonary DiseaseNDA submission planned H1 2018 by partner AstraZeneca Filing supported...

Original Article: Circassia Announces Duaklir Successfully Met Primary Endpoints In AMPLIFY Phase III Study In Chronic Obstructive Pulmonary Disease

NEXT ARTICLE

More From BioPortfolio on "Circassia Announces Duaklir Successfully Met Primary Endpoints In AMPLIFY Phase III Study In Chronic Obstructive Pulmonary Disease"

Quick Search
Advertisement
 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

COPD (chronic obstructive pulmonary disease)
COPD (chronic obstructive pulmonary disease) is used for a number of conditions including chronic bronchitis and emphysema, which all  lead to the airways in the lungs becoming damaged and thus narrower,  making inhalation and exhalation harder...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...